Clinical trial
Study of DF1001 in Patients with Advanced Solid Tumors
NCT04143711 · Dragonfly Therapeutics, Industry · Recruiting
Key facts
| NCT number | NCT04143711 |
|---|---|
| Title | Study of DF1001 in Patients with Advanced Solid Tumors |
| Official title | A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications |
| Lead sponsor | Dragonfly Therapeutics, Industry |
| Status | Recruiting |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Solid Tumor, Adult |
| Intervention type | Drug |
| Interventions | DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy |
| Enrollment | 378 |
| Start date | Nov 11, 2019 |
| Primary completion | Oct 1, 2026 |
| Completion | Dec 1, 2026 |
| First posted | Oct 29, 2019 |
| Last update posted | Mar 19, 2025 |
| Countries | Belgium, Denmark, France, Netherlands, South Korea, United States |
At a glance
- 10–99 Study sites
- No Results posted
- 10–99 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: